Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2022 Feb 9

PMID 35138920

Authors

Timothy A Yap

Erika Hamilton

Todd Bauer

Ecaterina E Dumbrava

Rinath Jeselsohn

Aaron Enke

Sabrina Hurley

Kevin K Lin

Jenn Habeck

Heidi Giordano

Geoffrey I Shapiro

Affiliations

Soon will be listed here.

Citing Articles

Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.

Jiang K, Wang S Transl Breast Cancer Res. 2025; 6:9.

PMID: 39980806 PMC: 11836745. DOI: 10.21037/tbcr-24-38.

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Meric-Bernstam F, Yuca E, Evans K, Zhao M, Maejima T, Karibe T Clin Cancer Res. 2024; 31(3):573-587.

PMID: 39585341 PMC: 11788653. DOI: 10.1158/1078-0432.CCR-24-1948.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.

Drew Y, Zenke F, Curtin N Nat Rev Drug Discov. 2024; 24(1):19-39.

PMID: 39533099 DOI: 10.1038/s41573-024-01060-w.

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.

Kulkarni S, Gajjar K, Madhusudan S Front Oncol. 2024; 14:1414112.

PMID: 39135999 PMC: 11317305. DOI: 10.3389/fonc.2024.1414112.

Antibody-drug conjugates combinations in cancer treatment.

Pretelli G, Mati K, Motta L, Stathis A Explor Target Antitumor Ther. 2024; 5(3):714-741.

PMID: 38966169 PMC: 11222717. DOI: 10.37349/etat.2024.00243.

References

Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26(22):3785-90. DOI: 10.1200/JCO.2008.16.0812. View

Innocenti F, Kroetz D, Schuetz E, Dolan M, Ramirez J, Relling M . Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009; 27(16):2604-14. PMC: 2690389. DOI: 10.1200/JCO.2008.20.6300. View

Rose M, Burgess J, OByrne K, Richard D, Bolderson E . PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020; 8:564601. PMC: 7509090. DOI: 10.3389/fcell.2020.564601. View

Chen E, Jonker D, Siu L, McKeever K, Keller D, Wells J . A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs. 2016; 34(4):450-7. DOI: 10.1007/s10637-016-0351-x. View

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow J . Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014; 349(3):408-16. PMC: 4019318. DOI: 10.1124/jpet.113.210146. View

Smith L, Willmore E, Austin C, Curtin N . The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res. 2005; 11(23):8449-57. DOI: 10.1158/1078-0432.CCR-05-1224. View

Pilie P, Gay C, Byers L, OConnor M, Yap T . PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. Clin Cancer Res. 2019; 25(13):3759-3771. DOI: 10.1158/1078-0432.CCR-18-0968. View

Stepan L, Trueblood E, Hale K, Babcook J, Borges L, Sutherland C . Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59(7):701-10. PMC: 3201164. DOI: 10.1369/0022155411410430. View

Kummar S, Chen A, Ji J, Zhang Y, Reid J, Ames M . Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011; 71(17):5626-34. PMC: 3166628. DOI: 10.1158/0008-5472.CAN-11-1227. View

10.

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

11.

Ame J, Spenlehauer C, de Murcia G . The PARP superfamily. Bioessays. 2004; 26(8):882-93. DOI: 10.1002/bies.20085. View

12.

Seiter K . Toxicity of the topoisomerase I inhibitors. Expert Opin Drug Saf. 2005; 4(1):45-53. DOI: 10.1517/14740338.4.1.45. View

13.

Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A . Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2011; 30(4):1493-500. DOI: 10.1007/s10637-011-9682-9. View

14.

Tsang E, Dhawan M, Pacaud R, Thomas S, Grabowsky J, Wilch L . Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024; 8:e2300494. DOI: 10.1200/PO.23.00494. View

15.

Ocean A, Starodub A, Bardia A, Vahdat L, Isakoff S, Guarino M . Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017; 123(19):3843-3854. DOI: 10.1002/cncr.30789. View

16.

Bardia A, Messersmith W, Kio E, Berlin J, Vahdat L, Masters G . Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021; 32(6):746-756. DOI: 10.1016/j.annonc.2021.03.005. View

17.

Znojek P, Willmore E, Curtin N . Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer. 2014; 111(7):1319-26. PMC: 4183837. DOI: 10.1038/bjc.2014.378. View

18.

Rhodes K, Zhang W, Yang D, Press O, Gordon M, Vallbohmer D . ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2009; 1(1):23-30. DOI: 10.2174/187231207779814328. View

19.

Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y . The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol Cancer Ther. 2014; 13(5):1170-80. DOI: 10.1158/1535-7163.MCT-13-0683. View

20.

Liu X, Cheng D, Kuang Q, Liu G, Xu W . Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2013; 14(2):120-9. PMC: 3992871. DOI: 10.1038/tpj.2013.10. View